NCT02786732

Study to Evaluate Broadlumab vs Placebo and Ustekinumab

Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: MedDerm Associates · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

The purpose of the study is to evaluate the efficacy and safety of Induction and Maintenance Regimens of Brodalumab compared with Placebo and Ustekinumab in subjects with moderate to severe plaque psoriasis.

Detailed description

The study is up to 5 years. If you qualify, you will be randomized into 1 of 4 groups. Two groups will get brodalumab(1 group will get 210milligrams of brodalumab at each dose and the other group will get 140 milligrams of brodalumab at each dose), one group will get ustekinumab, and one group will get placebo.

Conditions

• Psoriasis

Interventions

Type	Name	Description
BIOLOGICAL	210mg Brodalumab	Brodalumab 210mg administered subcutaneously
BIOLOGICAL	140mg Brodalumab	Brodalumab 140mg administered subcutaneously
BIOLOGICAL	Ustekinumab	Ustekinumab 45mg or 90mg adminstered subcutaneously
BIOLOGICAL	Placebo	Placebo administered subcutaneously

Timeline

• Start date: 2012-08-01
• Primary completion: 2017-06-01
• Completion: 2017-10-01
• First posted: 2016-06-01
• Last updated: 2016-06-01

Locations

1 site across 1 country: United States